Good morning :)
Place Order
Add to Watchlist

KOBO Biotech Ltd

KOBO

KOBO Biotech Ltd

KOBO
Health CarePharmaceuticals
SmallcapWith a market cap of ₹7 cr, stock is ranked 4,482
High RiskStock is 4.05x as volatile as Nifty
2.901.69% (-0.05)
2.901.69% (-0.05)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹7 cr, stock is ranked 4,482
High RiskStock is 4.05x as volatile as Nifty
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

Avg

Average profitability - not good, not bad

Entry point

Avg

The stock is not in the overbought zone

Red flags

Avg

The stock has a moderate number of red flags

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹7 cr, stock is ranked 4,482
High RiskStock is 4.05x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
-1.43-0.06
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.916.640.47%

Forecast & Ratings

Detailed Forecast 
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Avon Lifesciences is engaged in the pharmaceutical business.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Lower than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of -7.79%, vs industry avg of 9.03%

Constant Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share stayed at 0%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue32.966.000.040.030.030.040.020.020.020.02
Raw Materialssubtract11.100.000.000.000.000.000.000.000.870.99
Power & Fuel Costsubtract2.030.280.240.310.420.280.100.12
Employee Costsubtract4.273.112.422.081.801.390.720.23
Selling & Administrative Expensessubtract0.960.160.110.210.140.150.110.14
Operating & Other expensessubtract9.370.490.251.30-1.670.979.571.01
Depreciation/Amortizationsubtract7.316.786.446.155.885.644.614.074.074.07
Interest & Other Itemssubtract14.3714.4114.5014.4414.4710.840.130.000.00
Taxes & Other Itemssubtract0.000.000.000.000.000.000.000.000.00
EPS-7.12-8.09-10.04-10.27-8.82-8.07-6.39-2.33-2.07-2.12
DPS0.000.000.000.000.000.000.000.000.000.00
Payout ratio0.000.000.000.000.000.000.000.000.000.00

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
KOBO Biotech Ltd-1.46-0.06
Sun Pharmaceutical Industries Ltd48.196.880.70%
Cipla Ltd32.685.020.78%
Torrent Pharmaceuticals Ltd68.9816.660.83%

Price Comparison

Compare KOBO with any stock or ETF
Compare KOBO with any stock or ETF
KOBO
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding44.95%0.00%0.66%0.00%54.39%

Jun 2023

Sep 2023

Dec 2023

Mar 2024

Shareholding History

Dec '22MarJunSepDec '23Mar0.00%0.00%0.00%0.00%0.00%0.00%

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

KOBO has not given any dividends in last 5 years

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateSep 21, 2012

Final
Final | Div/Share: ₹1.00

Dividend/Share

1.00

Ex DateEx Date

Sep 21, 2012

Cash Dividend

Ex DateEx DateJul 22, 2011

Final
Final | Div/Share: ₹1.00

Dividend/Share

1.00

Ex DateEx Date

Jul 22, 2011

News & Opinions
Earnings
Kobo Biotech reports standalone net loss of Rs 1.33 crore in the June 2024 quarter

Net Loss of Kobo Biotech reported to Rs 1.33 crore in the quarter ended June 2024 as against net loss of Rs 1.23 crore during the previous quarter ended June 2023. There were no Sales reported in the quarter ended June 2024 and during the previous quarter ended June 2023.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Kobo Biotech to discuss results

Kobo Biotech will hold a meeting of the Board of Directors of the Company on 14 August 2024.Powered by Capital Market - Live

1 month agoCapital Market - Live